[1]
Rosenblum, PhD, A., Cruciani, MD, PhD, R.A., Strain, MD, E.C., Cleland, PhD, C.M., Joseph, PhD, H., Magura, PhD, CSW, S., Marsch, PhD, L.A., McNicholas, MD, PhD, L.F., Savage, MD, MS, S.R., Sundaram, BA, A. and Portenoy, MD, R.K. 2012. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: Development and pilot test of a clinical protocol. Journal of Opioid Management. 8, 6 (Nov. 2012). DOI:https://doi.org/10.5055/jom.2012.0137.